SCHEMBL3406735

SCHEMBL3406735

CSc1ccc(C=O)cc1SC

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.52
KDM4E B2RXH2 1/20 0.46
PTGS2 P35354 1/20 0.46
RAB9A P51151 1/20 0.46
TSHR P16473 1/20 0.42
CYP2A6 P11509 6/20 0.41
TDP1 Q9NUW8 2/20 0.38
ALDH5A1 P51649 2/20 0.38
ABAT P80404 2/20 0.38
AOX1 Q06278 1/20 0.38
TRIM24 O15164 1/20 0.38
HPGD P15428 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
TYR P14679 1/20 0.37
CYP2A13 Q16696 1/20 0.37
HSD17B10 Q99714 2/20 0.36
FDPS P14324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376315 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL6436517 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL1575198 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL1576019 0.81 ALDH1A1 (0.47) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL11856373 0.81 KDM4E (0.57) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL19923143 0.81 KDM4E (0.57) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL1575377 0.81 ALDH1A1 (0.57) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL20529249 0.81 ALDH1A1 (0.47) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL7951906 0.81 ALDH1A1 (0.47) ALDH1A1KDM4EPTGS2RAB9ATSHR
SCHEMBL5760222 0.81 ALDH1A3 (0.47) ALDH1A1KDM4EPTGS2RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0035624-A2 Aldehydes F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-09-16 EP claimed
EP-0003212-A1 2.4-Diamino-5-benzylpyrimidines, pharmaceutical compositions containing them and their preparation F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-08-08 EP claimed
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 EP disclosed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 WO disclosed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 US disclosed
US-7381842-B2 Oxime ester photoinitiators CIBA SPECIALTY CHEMICALS CORPORATION (US) 2008-06-03 US disclosed
US-6949678-B2 Oxime ester photoinitiators CIBA SPECIALTY CHEMICALS CORP. (US) 2005-09-27 US disclosed
US-20050191567-A1 Oxime ester photoinitiators KUNIMOTO KAZUHIKO (JP) 2005-09-01 US disclosed
US-20010012596-A1 For resist applications; thermostability, storage stability CIBA SPECIALTY CHEMICALS CORP. 2001-08-09 US disclosed
EP-0032395-B1 BENZYLPYRIMIDINES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-03-23 EP disclosed
EP-0003212-B1 2.4-DIAMINO-5-BENZYLPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-03-17 EP disclosed
EP-0035624-A2 Aldehydes F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-09-16 EP disclosed
EP-0035624-A2 Aldehydes F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-09-16 EP disclosed
EP-0032395-A1 Benzylpyrimidines F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-07-22 EP disclosed
EP-0003212-A1 2.4-Diamino-5-benzylpyrimidines, pharmaceutical compositions containing them and their preparation F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-08-08 EP disclosed
EP-0003212-A1 2.4-Diamino-5-benzylpyrimidines, pharmaceutical compositions containing them and their preparation F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD ALDH1A1 3181/4885KDM4E 1194/4885PTGS2 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.